Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists

Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.

Detalles Bibliográficos
Autores principales: Pagliarello, Calogero, Girardelli, Carlo Renè, Stanganelli, Ignazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099294/
https://www.ncbi.nlm.nih.gov/pubmed/37063400
http://dx.doi.org/10.4081/dr.2022.9534
_version_ 1785025026506883072
author Pagliarello, Calogero
Girardelli, Carlo Renè
Stanganelli, Ignazio
author_facet Pagliarello, Calogero
Girardelli, Carlo Renè
Stanganelli, Ignazio
author_sort Pagliarello, Calogero
collection PubMed
description Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.
format Online
Article
Text
id pubmed-10099294
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-100992942023-04-14 Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists Pagliarello, Calogero Girardelli, Carlo Renè Stanganelli, Ignazio Dermatol Reports Case Report Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas. PAGEPress Publications, Pavia, Italy 2022-07-07 /pmc/articles/PMC10099294/ /pubmed/37063400 http://dx.doi.org/10.4081/dr.2022.9534 Text en ©Copyright: the Author(s) https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Report
Pagliarello, Calogero
Girardelli, Carlo Renè
Stanganelli, Ignazio
Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title_full Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title_fullStr Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title_full_unstemmed Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title_short Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
title_sort eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099294/
https://www.ncbi.nlm.nih.gov/pubmed/37063400
http://dx.doi.org/10.4081/dr.2022.9534
work_keys_str_mv AT pagliarellocalogero eruptivebasalcellcarcinomaandlenalidomiderisingawarenessamongdermatologists
AT girardellicarlorene eruptivebasalcellcarcinomaandlenalidomiderisingawarenessamongdermatologists
AT stanganelliignazio eruptivebasalcellcarcinomaandlenalidomiderisingawarenessamongdermatologists

Ejemplares similares